|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
<b>Purpose:</b> COX-2 overexpression and elevated levels of prostaglandin E2 (PGE2) play an important role in breast cancer carcinogenesis.
|
31534346 |
2019 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
1.There are numerous investigations demonstrating that the cyclooxygenase-2 (COX-2) inhibitors might enhance the efficiency of anastrozole in breast cancer.
|
28906164 |
2018 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
15-Deoxy-Δ<sup>12,14</sup>-prostaglandin J<sub>2</sub> (15d-PGJ<sub>2</sub>), one of the terminal products of cyclooxygenase-2-catalized arachidonic acid metabolism, has been shown to stimulate breast cancer cell proliferation and migration through Akt activation, but the underlying mechanisms remain poorly understood.
|
29550515 |
2018 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Breast cancer cell cyclooxygenase-2 expression alters extracellular matrix structure and function and numbers of cancer associated fibroblasts.
|
28152501 |
2017 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
COX-2 and HER2 expression were also analyzed in human breast cancer cell lines (MCF-7, MCF-7/HER2, SK-BR-3, and MDA-MB-231) by immunoblotting.
|
11912139 |
2002 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
COX-2 and PPARgamma can be promising molecular targets for combinational chemoprevention or treatment of breast cancer.
|
12736714 |
2003 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Cyclooxygenase-2 (COX-2) overexpression is a widely recognized feature of human breast cancer and inhibitors of the enzyme have antitumor effects in a subset of tumor settings.
|
15967164 |
2005 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
COX-2 induction by heparanase in the progression of breast cancer.
|
16391819 |
2006 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
COX-2 is highly expressed in LIN, supporting a role for this protein in the early stage of breast carcinogenesis, representing the rationale for using COX-2 selective inhibitors in the earliest stages of breast cancer.
|
17542993 |
2007 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
COX-2 inhibitors prevent chemoresistance development in breast cancer cells by inhibiting P-gp expression and function by a mechanism that involves PGH2 generation and NF-kappaB activation.
|
19940361 |
2009 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
COX-2 was significantly associated with breast cancer outcome in ER-negative [Hazard ratio (HR) = 2.72; 95% confidence interval (CI), 1.36-5.41; comparing high versus low COX-2] and HER2 overexpressing breast cancer (HR = 2.84; 95% CI, 1.07-7.52).
|
21078168 |
2010 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cyclooxygenase-2 (COX-2) is a potential molecular prognostic factor for breast cancer, and calcitriol [1,25(OH)(2)D(3)], the biologically active form of vitamin D, is a promising target in breast cancer therapy.
|
22213327 |
2012 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
COX-2 expression has been associated with a number of tumors, including breast cancer, where its expression is associated with poor prognoses.
|
23275522 |
2012 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
COX-2-null MCF-7 human breast cancer cells, MCF-7 cells transiently expressing COX-2 and COX-2-expressing MDA-MB-231 cells were employed.
|
24325753 |
2014 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Cyclooxygenase-2 (COX-2) and matrix metalloproteinase‑9 (MMP-9) are highly expressed in various cancers, such as colon, lung and breast cancer, and enhance cell migration and metastasis in vitro and in vivo.
|
24859472 |
2014 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
COX-2 expression is associated with proliferation, apoptosis and invasion of breast cancer cells, and its mechanisms of action involve regulating expression of c-myc through the p38MAPK and Wnt/β-catenin pathways.
|
25374215 |
2014 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
COX-2-rs20417 CC genotype was significantly associated with increased risk of breast cancer when comparing to G allele [ORs were 1.231 (1.050-1.444) for CC vs. GG, P = 0.01, 1.223 (1.045-1.432) for CC vs. G carrier, P = 0.01].
|
25433948 |
2015 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
COX-2 protein expression was positive in 24.9% of the breast cancer samples.
|
25511800 |
2014 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cox-2 has been implicated in MD-related breast cancer risk, and was increased in stromal cells in high MD tissues in one study.
|
26227474 |
2015 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
COX-2(+) TAMs promoted breast cancer cell proliferation and survival by increasing Bcl-2 and P-gp and decreasing Bax in cancer cells.
|
26359357 |
2015 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
COX-2 will be a potential target for HPV16 E6-associated breast cancer.
|
29250535 |
2017 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
COX-2 Expression in Breast Carcinoma with Correlation to Clinicopathological Parameters
|
30051683 |
2018 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
COX-2 inhibitors should preferably be avoided during docetaxel use in patients with breast cancer who are undergoing NAC.
|
30702971 |
2019 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Cyclooxygenase-2 (COX-2) expression may be a driver of immunosuppression in breast cancer, but the mechanisms involved remain elusive.
|
31759380 |
2019 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A COX-2 inhibitor nimesulide analog selectively induces apoptosis in Her2 overexpressing breast cancer cells via cytochrome c dependent mechanisms.
|
19428334 |
2009 |